Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Lifyorli Coverage Update: Prior Auth | …
    Ask Trek AI about this page
    ModifiedQualChoicePolicy CP.PHAR.736

    Relacorilant (Lifyorli) coverage for platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.736 alerts

    Get alerted when Policy CP.PHAR.736 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines medical necessity and prior authorization criteria for relacorilant (Lifyorli) when used in combination with nab‑paclitaxel for adults with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, and provides continuation, dosing, contraindication, and related guidance affecting commercial, HIM/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerQualChoice
    PolicyRelacorilant (Lifyorli) coverage for platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer
    Policy CodePolicy CP.PHAR.736
    Change TypeAdded criteria for new FDA‑approved indication
    Effective DateJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization demonstrating diagnosis, prescriber specialty, age, platinum‑resistant disease, prior regimens (1–3 with at least one including bevacizumab), combination with nab‑paclitaxel, and dosing limits.
    SourceLink
    POLICY UPDATE CHANGES

    Criteria added for the new FDA‑approved indication of relacorilant (Lifyorli) for platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with nab‑paclitaxel.

    Adults ≥18minimum age for coverage
    1–3prior systemic regimens required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    150 mg
    per‑dose regimen
    12 monthsapproval duration
    25 mg,100 mgproduct availability

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met for initial therapy:

    Initial Approval — Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer: 1. Diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Disease is platinum‑resistant (i.e., disease progressed < 6 months from completion of a platinum‑containing therapy); 5. Member has received 1 to 3 prior systemic treatment regimens, at least one of which included bevacizumab; 6. Lifyorli is not prescribed concurrently with systemic glucocorticoids used for a lifesaving indication (e.g., immunosuppression after organ transplantation); 7. Prescribed in combination with nab‑paclitaxel; 8. Request does not exceed any of the following: (a) 150 mg on the day before, the day of, and the day after each nab‑paclitaxel infusion; (b) 3 capsules per dose; (c) 9 doses per 28 days; 9. Dose is at least 125 mg per dose.see nodes

    Initial approval duration = 12 months.

    Continuation Therapy

    Covered when ALL of the following are met for continued therapy:

    Continuation Therapy — Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer: 1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Lifyorli for a covered indication and has received this medication for at least 30 days; 2. Member is responding positively to therapy; 3. Prescribed in combination with nab‑paclitaxel; 4. If request is for a dose increase, request does not exceed any of the following: (a) 150 mg on the day before, the day of, and the day after each nab‑paclitaxel infusion; (b) 3 capsules per dose; (c) 9 doses per 28 days; 5. Dose is at least 125 mg per dose.see nodes

    Continued approval duration = 12 months.

    Coverage is not authorized for non‑FDA approved indications that are not specifically addressed in this policy unless the request is supported by sufficient documentation of efficacy and safety in accordance with applicable off‑label use policies: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid, or other evidence of coverage documents.

    Coverage and administration of benefits for relacorilant (Lifyorli) are subject to the specific terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy or contract). These contractual provisions, together with applicable state and federal requirements and Health Plan administrative policies, govern eligibility for coverage and payment and may limit or exclude coverage when they apply.

    Concurrent systemic glucocorticoid therapy used for a lifesaving indication (for example, immunosuppression after organ transplantation) is a contraindication to relacorilant and is not medically necessary for coverage when present. Requests that indicate concurrent systemic glucocorticoids for lifesaving purposes should be denied per this contraindication check.

    Coding & Definitions

    inv-06: Platinum‑resistant definition — Progression < 6 months from completion of a platinum‑containing therapy
    DefinitionProgression less than 6 months from completion of a platinum-containing therapy
    ContextUsed to determine eligibility for Lifyorli (relacorilant) in platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Placement in criteriaRequired element for initial and continuation approval (coverage criteria items reference disease progressed < 6 months)

    Provider Actions & Prior Authorization

    Prior Authorization

    Prior authorization required for Lifyorli (relacorilant)

    Prior authorization is required. The request must document the diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer; that the prescriber is an oncologist or consulted an oncologist; the member is ≥18 years; disease is platinum‑resistant (progression <6 months from completion of a platinum‑containing therapy); the member has received 1–3 prior systemic regimens with at least one including bevacizumab; Lifyorli will be given in combination with nab‑paclitaxel; dosing limits (150 mg on the day before, day of, and day after each nab‑paclitaxel infusion; maximum 3 capsules per dose; maximum 9 doses per 28 days; minimum dose 125 mg) are met; and contraindication checks (e.g., not given concurrently with systemic glucocorticoids for a lifesaving indication) are addressed.

    • Must show member received 1–3 prior systemic regimens, at least one including bevacizumab
    • Must confirm combination administration with nab‑paclitaxel and adherence to dosing limits
    • Prescriber is an oncologist or in consultation with oncology
    Note

    Policy guides prior authorization/coverage decisions

    Background

    Relacorilant (Lifyorli) is a glucocorticoid receptor antagonist recently approved by the FDA in combination with nab‑paclitaxel for adults with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic regimens, at least one of which included bevacizumab. The pivotal approval and policy criteria reference key trial evidence (including the phase 3 ROSELLA trial) and align dosing with the product regimen: 150 mg orally on the day before, the day of, and the day after each nab‑paclitaxel infusion, with allowance to reduce to 125 mg for adverse reactions; dosing limits include a maximum of 3 capsules per dose and 9 doses per 28 days.

    Definitions

    inv-16: Platinum‑resistant — Disease progression less than 6 months from completion of a platinum‑containing therapy
    Platinum‑resistant — clinical definitionDisease progression less than 6 months from completion of a platinum-containing therapy
    Role in approvalMust be met for initial approval (coverage criteria item 4) and for continuation decisions
    DocumentationProviders must submit clinical documentation supporting platinum‑resistant status (e.g., chart notes, imaging, labs) per prior authorization requirements
    inv-17: Health Plan — definition for plans adopting this clinical policy and administered by Centene
    Health Plan — definitionA health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates
    Implication

    Initial Therapy — Dosing & Requirements

    Initial Therapy Dosing

    Initial dosing and administration: 150 mg PO once on the day before, the day of, and the day after each nab‑paclitaxel infusion; nab‑paclitaxel is recommended on days 1, 8, and 15 of each 28‑day cycle. May reduce to 125 mg for adverse reactions; if unable to tolerate after one dose reduction, discontinue.max 150 mg per dose; min 125 mg per dose; max 3 capsules per dose; max 9 doses per 28 days.

    Continuation Therapy Criteria

    Continuation Therapy

    Continuation: See coverage continuation criteria: currently receiving or at least 30 days of therapy; positive response to therapy; prescribed in combination with nab‑paclitaxel; if request is for dose increase, request must not exceed: 150 mg on the day before, the day of, and the day after each nab‑paclitaxel infusion; 3 capsules per dose; 9 doses per 28 days; dose must be at least 125 mg per dose.see nodes

    Continued approval duration = 12 months.

    Step Therapy & Therapeutic Alternatives

    Therapeutic alternativeExamples / regimen notes
    carboplatin + paclitaxel ± bevacizumabListed as a systemic therapy option; dosing varies (see regimen references).
    paclitaxel + cisplatinListed as a systemic therapy option; dosing varies.
    carboplatin + doxorubicinListed as a systemic therapy option; dosing varies.
    docetaxel + carboplatin ± bevacizumabListed as a systemic therapy option; dosing varies.
    FOLFOX (fluorouracil + oxaliplatin + leucovorin) ± bevacizumabListed as a systemic therapy option; dosing varies.
    capecitabine + oxaliplatin ± bevacizumabListed as a systemic therapy option; dosing varies.
    cyclophosphamide + bevacizumabListed as a systemic therapy option; dosing varies.
    docetaxel (single agent)Listed as a systemic therapy option; dosing varies.
    etoposideListed as a systemic therapy option; dosing varies.
    gemcitabineListed as a systemic therapy option; dosing varies.
    doxorubicin ± bevacizumabListed as a systemic therapy option; dosing varies.
    topotecanListed as a systemic therapy option; dosing varies.
    capecitabine (single agent)Listed as a systemic therapy option; dosing varies.
    pemetrexedListed as a systemic therapy option; dosing varies.
    vinorelbineListed as a systemic therapy option; dosing varies.
    ifosfamideListed as a systemic therapy option; dosing varies.

    Quantity Limits & Dosing

    inv-21: Lifyorli (relacorilant) — standard per-dose regimen 150 mg (may reduce to 125 mg); max 3 capsules per dose; max 9 doses per 28 days
    Standard per-dose regimen150 mg PO once on the day before, the day of, and the day after each nab-paclitaxel infusion (standard per-dose = 150 mg)
    Dose reductionMay be reduced to 125 mg for adverse reactions; if unable to tolerate after one dose reduction, discontinue
    Capsule limit per doseMaximum 3 capsules per dose
    Doses per cycle limitMaximum 9 doses per 28 days

    Site of Care

    Note

    Site of care & administration schedule — oral with nab‑paclitaxel

    Lifyorli is administered orally per the dosing schedule in combination with nab‑paclitaxel; nab‑paclitaxel is recommended on days 1, 8, and 15 of each 28‑day cycle, and Lifyorli is given the day before, the day of, and the day after each infusion.

    • Setting: office or infusion center
    • Nab‑paclitaxel schedule: days 1, 8, and 15 of a 28‑day cycle
    • Lifyorli dosing days: day before, day of, and day after each nab‑paclitaxel infusion
    Policy Summary
    PayerQualChoice
    PolicyRelacorilant (Lifyorli) coverage for platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer
    Policy CodePolicy CP.PHAR.736
    Change TypeAdded criteria for new FDA‑approved indication
    Effective DateJun 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization demonstrating diagnosis, prescriber specialty, age, platinum‑resistant disease, prior regimens (1–3 with at least one including bevacizumab), combination with nab‑paclitaxel, and dosing limits.
    SourceLink
    On This Page
    Coverage CriteriaCoding & DefinitionsProvider Actions & Prior AuthorizationBackgroundDefinitionsInitial Therapy — Dosing & RequirementsContinuation Therapy CriteriaStep Therapy & Therapeutic AlternativesQuantity Limits & DosingSite of Care

    This clinical policy is intended to guide medical necessity determinations and may be used by the Health Plan to make prior authorization and coverage decisions for relacorilant (Lifyorli).

    Step Therapy

    Therapeutic alternatives per Appendix B

    Preferred and alternative systemic chemotherapy regimens are listed in Appendix B and may be considered or required per formulary and line‑of‑business policies; examples include carboplatin/paclitaxel ± bevacizumab, paclitaxel/cisplatin, carboplatin/doxorubicin, docetaxel/carboplatin ± bevacizumab, fluorouracil/oxaliplatin/leucovorin ± bevacizumab, capecitabine/oxaliplatin ± bevacizumab, single‑agent options (docetaxel, etoposide, gemcitabine, topotecan, capecitabine, pemetrexed, vinorelbine, ifosfamide), and combinations with bevacizumab as listed.

    • Therapeutic alternatives may not be formulary agents for all lines of business and may require prior authorization
    • Use may be constrained by formulary/line‑of‑business step policies
    Note

    Provider must follow policy requirements when requesting coverage

    Providers must ensure requests adhere to all policy requirements and supply clinical justification consistent with the approval criteria when seeking coverage for Lifyorli.

    Documentation Required

    Required documentation to support authorization

    Submit supporting clinical documentation with the authorization request — for example, office chart notes, lab results, prior treatment records, and other clinical information that demonstrate the member meets all approval criteria (diagnosis, platinum‑resistant status, prior regimens including bevacizumab, prescriber specialty, dosing plan, and response for continuation requests).

    • Include documentation of prior systemic regimens and at least one bevacizumab‑containing regimen
    • Document platinum‑resistant status (progression <6 months after platinum therapy) and current response for continuation requests
    Billing Rule

    Follow member coverage terms, conditions, exclusions, and limitations

    Coverage and administration of benefits are subject to the member's coverage documents (e.g., evidence of coverage, certificate of coverage, policy or contract); providers must follow those terms, conditions, exclusions, and limitations when submitting claims or requests.

    Denial Risk

    Denial triggers for unsupported or undocumented requests

    Requests for non‑FDA approved indications that are not supported by sufficient evidence per applicable off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) or lack required documentation that the member meets approval criteria will be denied.

    • Non‑FDA indications require sufficient off‑label documentation per plan policies
    • Missing required clinical documentation may trigger denial
    Note

    Coverage administration subject to member coverage documents

    All coverage decisions and the administration of benefits for Lifyorli remain subject to the specific terms, conditions, exclusions, and limitations of the member's coverage documents and applicable plan policies and procedures.

    Policy content is a guide to medical necessity and may be used to assist in coverage decisions and administration of benefits
    Not a contractThis clinical policy does not constitute a contract, guarantee of payment, or medical advice; coverage remains subject to member coverage documents and applicable law